Safety profile of nivolumab administered as 30-minute (min) infusion: Analysis of data from CheckMate 153

Authors :: Leora Horn
Michael McCleod
Ben C. Creelan
David R. Spigel
Nivedita Aanur
Kenneth B. Blankstein
Mohamed K. Mohamed
Ang Li
Tarek Mekhail
Petros Nikolinakos
Shruti Agrawal
David M. Waterhouse
Craig H. Reynolds
Ian M. Waxman
Jason C. Chandler
Source :: Journal of Clinical Oncology. 34:3059-3059
Publication Year :: 2016
Publisher :: American Society of Clinical Oncology (ASCO), 2016.
Abstract: 3059Background: Nivolumab,aprogrammed death-1 (PD-1) immune checkpoint inhibitor, is approved in the US for previously treated metastatic NSCLC and renal cell carcinoma, and for advanced melanoma, ...

Subjects :: Oncology
Cancer Research
medicine.medical_specialty
business.industry
Immune checkpoint inhibitors
Checkmate
medicine.disease
Safety profile
Renal cell carcinoma
Internal medicine
medicine
Nivolumab
Previously treated
business
neoplasms
Advanced melanoma

Tools